Nacimbio

Nacimbio, or the National Immunobiological Company, is a major Russian pharmaceutical holding company founded in 2013 under the Rostec State Corporation. It acts as a strategic entity responsible for ensuring Russia's independence from imported medicines, particularly vaccines and blood products. The company oversees a vast network of manufacturing and research facilities, including Microgen and FORT, which produce a significant portion of the vaccines required for the Russian National Immunization Schedule. Nacimbio's portfolio features innovative products such as the quadrivalent influenza vaccine Ultrix Quadri and various bacteriophage-based therapies. Beyond vaccines, the company is a leader in the production of human plasma-derived medicines and medical equipment.